Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 23k
14 July 2015
E-011302-15
Question for written answer E-011302-15
to the Commission
Rule 130
Christel Schaldemose (S&D)

 Subject:  Diabetes costs
 Answer in writing 

In 2012, the London School of Economics carried out a study, which calculated that the indirect costs associated with diabetes (such as reduced productivity, absenteeism, early retirement, social expenditure and expenditure on care) in the five largest countries amount to a total of EUR 98.4 billion. Added to this there are the direct costs of approximately EUR 90 billion. In total, therefore, diabetes costs the five largest countries alone EUR 188.4 billion per year.

Can the Commission confirm these figures?

In light of these high costs, what measures does it plan to take over and above the current CHRODIS Joint Action to ensure that treatment is optimised in order to reduce these unnecessary indirect costs as much as possible and to improve the quality of life of diabetes patients in Europe?

Original language of question: DA 
Legal notice - Privacy policy